Adipotide (FTPP) is a chimeric peptidomimetic (MW ~3,200 g/mol) composed of a prohibitin-targeting domain (CKGGRAKDC) linked to a proapoptotic domain D(KLAKLAK)2. It selectively targets and destroys blood vessels supplying white adipose tissue, causing rapid fat loss through vascular disruption and subsequent adipocyte death. In rhesus monkeys, it produced 11% weight loss in 4 weeks. Clinical development was discontinued due to reversible kidney toxicity observed in primate studies.
1 independent Janoshik purity test cover Adipotide across 1 vendor.
Category: Experimental Fat Loss. Evidence rating: D (animal/preclinical only).
Clinical status: Clinical development discontinued. Preclinical only (primate proof-of-concept). No human trials conducted.
Adipotide has a dual-domain design. The homing peptide CKGGRAKDC binds to prohibitin on the surface of endothelial cells in white adipose tissue vasculature (prohibitin is overexpressed on fat tissue blood vessels). Once bound, the proapoptotic D(KLAKLAK)2 domain disrupts mitochondrial membranes…
Safety considerations: CRITICAL: Reversible kidney toxicity observed in all primate studies; Mechanism: prohibitin expression in kidney proximal tubule cells causes off-target damage; Elevated BUN and creatinine during treatment; reversed after discontinuation.
Reviewed by the PeptideAtlas Editorial Team.
| Amino-acid sequence | CKGGRAKDC-GG-D(KLAKLAK)2 |
|---|---|
| Molecular weight | ~3,200 g/mol |
| Half-life | ~2-4 hours (estimated) |
| Production method | synthetic |
| Anti-doping status | not-listed |
| US regulatory status | Not FDA-approved. Research compound only. Clinical development discontinued. |
| Vendor | Best tested purity |
|---|---|
| Qingdao Sigma Chemical QSC | 98.8% |
Despite dramatic fat loss in monkeys (11% body weight in 4 weeks), adipotide caused reversible but significant kidney damage because prohibitin is also expressed in renal proximal tubule cells. The therapeutic window was too narrow for safe clinical use.
Some grey-market research peptide vendors sell products labeled as Adipotide/FTPP. The identity, purity, and safety of these products is entirely unverified. Given the known kidney toxicity, self-administration carries serious risk.
Researchers have explored modifying the targeting domain to increase adipose selectivity and reduce prohibitin binding in kidney tissue, but no successful reformulation has been published. The fundamental challenge is that prohibitin expression in the kidney is a biological fact that cannot be easily circumvented by peptide engineering alone. The approach of vascular-targeted adipose destruction…
Vendors with independent lab tests for it: Qingdao Sigma Chemical QSC.